MK-677 (Ibutamoren) Long-Term Use: Why I Cycled Off After 8 Months

I ran MK-677 (ibutamoren) for eight months straight, and then I came off it. This is a field report on what actually happened — the good, the bad, and the specific reasons I decided to cycle off a compound a lot of people in this community treat as a permanent fixture in their stack.

If you’re considering MK-677 long-term, this is the article I wish I’d read before I started.

What MK-677 Is — Quick Refresher

MK-677 (also called ibutamoren) is an orally active ghrelin receptor agonist. It mimics ghrelin’s action on the pituitary, triggering a release of growth hormone and downstream IGF-1. Unlike actual growth hormone injections, MK-677 pushes your own pituitary to release endogenous GH — which keeps the pulse architecture more natural and avoids the negative feedback on your own production.

It’s not a SARM, despite often being shelved next to them. It doesn’t bind androgen receptors, doesn’t suppress testosterone, doesn’t require post-cycle therapy in the traditional sense. It’s a selective growth hormone secretagogue.

The pitch: GH and IGF-1 elevations comparable to low-to-moderate exogenous HGH doses, orally active, relatively cheap, no injections required.

The reality: more complicated than the pitch.

My Protocol

I ran 25 mg per day, taken before bed, for 8 months continuously. Single oral capsule. No cycling, no dose changes. The pre-bed timing leverages the natural GH pulse that happens during deep sleep — MK-677 amplifies that pulse rather than fighting against it.

Baseline labs before starting: total testosterone in upper normal range (on TRT), IGF-1 around 180 ng/mL, fasting glucose 88, HbA1c 5.1, prolactin within range, full lipid panel clean.

Re-labbed at month 2, month 4, month 6, and month 8.

What Worked

Sleep depth improved dramatically. This was the single most noticeable subjective effect. Deep sleep percentage on my wearable went from a consistent 18% baseline to 28-32% within the first three weeks. I woke up feeling more recovered. Resting heart rate at night dropped about 4 bpm. for sleep quality alone, MK-677 was the most effective compound I’ve ever run.

IGF-1 climbed steadily. Month 2 IGF-1 was 245. Month 4 was 290. Month 6 plateaued around 310. Month 8 was 315. That’s a meaningful elevation for a man my age and consistent with the published research on MK-677.

Recovery between training sessions improved noticeably. Six-day-a-week training started feeling more sustainable. Soreness resolved faster. I added back some volume that had been quietly creeping out of my program over the prior year.

Skin and nail quality improved. Subtle but real — skin felt better hydrated, nails grew noticeably faster. Hair was thicker on top of my existing protocol.

Muscle fullness improved. Not dramatic mass gain — about 4 lbs of scale weight over 8 months, most of which was likely water and glycogen from elevated GH — but visual muscle fullness was clearly better. Vascularity slightly reduced (from the intracellular water retention) but overall package looked better.

What Didn’t Work — and Why I Came Off

The reasons MK-677 is back on the shelf:

1. Insulin resistance was creeping up. By month 6, my fasting glucose had climbed from 88 to 102. HbA1c went from 5.1 to 5.6 — borderline pre-diabetic. This is a well-documented MK-677 effect: GH and IGF-1 elevations chronically opposed insulin action, the pancreas compensates, and over months you see fasting glucose and A1c drift up.

I’m not pre-diabetic genetically — both parents have clean metabolic panels — and my training and diet hadn’t changed. The compound was the variable. I added 500 mg metformin at night to try to manage it, which helped, but the underlying mechanism was unchanged.

2. Water retention got out of hand. Mild puffiness in the face and ankles started around month 3 and got progressively worse. By month 7, my morning weight was fluctuating by 4-6 pounds depending on sodium intake the day before. The look in the mirror at the gym was good. The look in photos that anyone else was taking was not — my face looked rounder than it should.

3. Appetite hijacking. Ibutamoren mimics ghrelin. Ghrelin is the hunger hormone. My appetite went through the roof. The first two months I appreciated it — easier to eat in a slight surplus, easier to push training calories. By month 5 I was fighting it. I’d eat dinner and an hour later be hungry again. Eating dinner late helped some, but the underlying drive was constant.

This is a feature for hardgainers trying to put on size. For someone trying to maintain or recompose, it’s an active disadvantage.

4. Slight tingling in the hands. Carpal tunnel-like symptoms in both hands by month 6. Worst in the mornings. This is a known GH side effect — fluid retention in the carpal tunnel compresses the median nerve. It wasn’t severe, but it was unmistakable and not improving.

5. The cost-benefit shifted. The first 90 days of MK-677 deliver almost all of the upside. The benefits plateau by month 4-5 while the side effects accumulate. That’s the wrong direction on a risk-reward curve.

The Coming-Off Experience

I stopped MK-677 cold turkey at the eight-month mark. No taper. The compound has a relatively short half-life (around 24 hours) so there’s no real PCT concern the way there is with anabolics — your own GH axis isn’t suppressed, it was just amplified.

What I noticed in the four weeks after stopping:

• Deep sleep dropped back to baseline within two weeks. This was the loss I felt most acutely.
• Fasting glucose normalized — back to 89 within three weeks.
• Water retention resolved over two weeks. Dropped 5 pounds of scale weight without changing anything else. Face looked sharper.
• Appetite normalized within a week. The constant hunger went away.
• Tingling in the hands resolved within a week.
• IGF-1 at week 4 post-discontinuation: 195 — close to baseline.
• Recovery and training capacity dropped slightly. Not back to pre-MK-677 baseline, but not as good as it was on cycle.

Would I Run It Again? Maybe — With Modifications

I’m not done with MK-677 forever. But I won’t run it the way I ran it the first time. Here’s what I’d change:

Cycle it. 12 weeks on, 12 weeks off — the way I’d cycle anything with significant metabolic impact. This gives the insulin sensitivity time to recover and prevents the slow drift into pre-diabetic territory.

Lower dose. 25 mg is the standard dose because that’s what the dropout-from-Phase-III-trials studies used. There’s evidence that 12.5 mg produces similar IGF-1 elevations with proportionally less appetite and water retention. I’d start at 12.5 mg next time and titrate up only if results were inadequate.

Run with metformin from day one. 500 mg at night, prophylactically, to keep the insulin sensitivity issue from developing in the first place.

Front-load the cycle. Recognize that most of the benefit comes in the first 8-12 weeks and design the cycle around that, rather than running it indefinitely past the point of diminishing returns.

Pair with cardio. Insulin resistance from MK-677 is largely manageable with increased zone 2 cardio and reduced refined carb intake. I underestimated this the first time.

Who MK-677 Is Right For — and Who It’s Not

Right for:

• Underweight men trying to gain size with appetite assistance built in.
• Men with diagnosed sleep architecture problems who want the deep-sleep amplification.
• Recovery-focused users coming back from injuries, willing to accept the metabolic trade-offs short-term.
• Men with low baseline IGF-1 (under 100 ng/mL) where the elevation actually brings them into a normal range rather than pushing past it.

Wrong for:

• Anyone with a family history of type 2 diabetes or pre-existing insulin resistance.
• Men trying to recompose or cut. The appetite drive fights you constantly.
• Men who don’t have monitoring infrastructure in place. Running MK-677 without regular labs is irresponsible.
• Men chasing the “permanent GH-elevation lifestyle” — the data on long-term use is sparse and what we have suggests cycling is wiser.

The Legal Status in 2026

MK-677 sits in the same research-chemical gray zone as the SARMs it gets shelved with. Not approved for human use, not scheduled, sold widely under research-only labeling. The post-RFK Jr. landscape I covered in my legal SARMs alternatives piece hasn’t moved the needle on MK-677 specifically — it remains where it’s always been. Vendor diligence is on you. Third-party HPLC, established suppliers, don’t chase the cheapest option.

The Bottom Line

MK-677 delivers on its core promise — meaningful IGF-1 elevation, improved sleep depth, faster recovery — for the first three or four months. Past that point, for most users, the metabolic side effects start to outweigh the diminishing benefits. The compound is best run as a defined 8-12 week cycle, at lower doses than the standard 25 mg, with metformin support, regular bloodwork, and a planned off-period to let insulin sensitivity reset.

I came off because the data my body was producing — glucose creep, water retention, carpal tunnel — was telling me to. That’s the framework I’d want anyone running this compound to operate from. Numbers, not feelings.

If you want growth hormone elevation as a permanent feature, low-dose actual HGH with proper monitoring is a more controllable tool than MK-677. If you want a focused 12-week recovery and sleep-quality boost, MK-677 done correctly is one of the better tools available. Match the tool to the goal.

Related Articles

• Omnitrope HGH for Young Lifters: longevity benefits vs risks Analysis
• HGH for young athletes: Benefits, Risks, and What you need to know
• Legal SARMs Alternatives: Tony Huge’s Take on 2025 Market
• Ultimate peptide stacking guide: how to combine peptides for maximum results
• Long-Term Testosterone Therapy Results: 7-Month Progress Report